Samengesteld · Gezondheidszorg

Biotech

Door InspectStocksPublished 14 okt 202619 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

Gegroepeerd met hulp van een AI-model en nagekeken door onze redactie. De regel onder elk bedrijf zegt waarom het hier staat.

Download image

Kaarten Niveaus

Aandelenkoersen zijn de slotkoersen van 11 nov 2026, uit de IEX-beursfeed.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29,0%

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap US$ 138,7BP/E 35,22
US$ 547,02+26,0%1Y
Since added +12,7%
B+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 13B+10,5%
Profit
US$ 4B+8,2%
Free cash flow
US$ 3,2B-4,0%
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$ 101,3BP/E 21,18
US$ 959,45+41,5%1Y
Since added +27,4%
C+
Groei en kasstroom
Groeit
Business trend
Versnellend
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 16,9B+18,6%
Profit
US$ 4,8B+5,2%
Free cash flow
US$ 3,8B-9,4%
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap US$ 210,5BGeen K/W (bedrijfsverlies)
US$ 169,73+40,9%1Y
Since added +14,8%
A
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Gemengd
Getting better
Verbetert
Revenue
US$ 31B+6,5%
Profit
US$ -3,9B-147,6%
Free cash flow
US$ 13,8B+50,4%
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$ 21,4BP/E 68,58
US$ 159,80-64,7%1Y
Since added -28,6%
B+
Groei en kasstroom
Groeit sterk
Business trend
Vertragend
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 3,7B+65,2%
Profit
US$ 2,6B+2.136,9%
Free cash flow
US$ 465,4M+1.192,7%
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap US$ 37,5BP/E 109,22
US$ 253,39+56,9%1Y
Since added +10,7%
A
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Solide
Getting better
Gemengd
Revenue
US$ 10,3B+2,3%
Profit
US$ 347,5M-78,4%
Free cash flow
US$ 2,1B-10,1%
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap US$ 26,5BGeen K/W (bedrijfsverlies)
US$ 120,64-37,9%1Y
Since added +24,7%
C-
Groei en kasstroom
Groeit
Business trend
Stabiel
Business quality
Zwak
Getting better
Gemengd
Revenue
US$ 1,5B+240,0%
Profit
US$ -605,6M+48,8%
Free cash flow
US$ -627,6M+30,7%
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap US$ 25,4BP/E 22,48
US$ 595,58+29,0%1Y
Since added +9,6%
C+
Groei en kasstroom
Groeit sterk
Business trend
Vertragend
Business quality
Sterk
Getting better
Verbetert sterk
Revenue
US$ 3,2B+1,9%
Profit
US$ 1,2B-3,2%
Free cash flow
US$ 867,2M-22,7%
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap US$ 17,6BP/E 25,87
US$ 174,35+18,7%1Y
Since added +29,0%
A+
Groei en kasstroom
Groeit sterk
Business trend
Versnellend
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 3,7B+38,0%
Profit
US$ 702,5M+64,1%
Free cash flow
US$ 1B+75,3%
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap US$ 100,6BGeen K/W (bedrijfsverlies)
US$ 248,70+831,1%1Y
Since added +15,0%
C-
Groei en kasstroom
Groeit
Business trend
Versnellend
Business quality
Zwak
Getting better
Verslechtert
Revenue
US$ 2,5B+13,1%
Profit
US$ -2,8B+10,5%
Free cash flow
US$ -2B+25,7%
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap US$ 11,3BNo P/E
US$ 58,32+5,4%1Y
Since added +7,3%
B
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Gemengd
Getting better
Verbetert
Revenue
US$ 3,7B+18,1%
Profit
US$ -19,1M-103,7%
Free cash flow
US$ 557,9M-33,0%
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap US$ 24,9BP/E 65,01
US$ 122,23+12,9%1Y
Since added +12,6%
C
Winst en boekwaarde
Groeit
Business quality
Gemengd
Getting better
Verbetert sterk
Revenue
US$ 6B+24,9%
Profit
US$ 403,4M-66,1%
Free cash flow
US$ 892,1MNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap US$ 17,3BP/E 21,17
US$ 70,71+62,2%1Y
Since added +18,8%
A+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 2,5B+9,1%
Profit
US$ 885,1M+30,6%
Free cash flow
US$ 1,2B+48,9%
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap US$ 22BGeen K/W (bedrijfsverlies)
US$ 87,64-21,5%1Y
Since added -1,5%
F
Groei en kasstroom
Gemengd
Business trend
Krimpend
Business quality
Gemengd
Getting better
Verbetert
Revenue
US$ 2,7B-23,2%
Profit
US$ -1,6B-157,7%
Free cash flow
US$ 314M+456,5%
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap US$ 15,9BP/E 80,84
US$ 248,18+81,5%1Y
Since added +18,0%
A
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Gemengd
Getting better
Verbetert
Revenue
US$ 4,7B+13,5%
Profit
US$ 206M+155,9%
Free cash flow
US$ 1,6B+21,3%
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap US$ 11,6BP/E 25,36
US$ 101,69+44,0%1Y
Since added -7,2%
A+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 1,8B+45,0%
Profit
US$ 485,4M-18,5%
Free cash flow
US$ 885,9M+47,1%
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap US$ 16,1BGeen K/W (bedrijfsverlies)
US$ 259,10+30,1%1Y
Since added +16,0%
D
Winst en boekwaarde
Gemengd
Business quality
Gemengd
Getting better
Verbetert
Revenue
US$ 1,2B+113,4%
Profit
US$ -254,8M+39,7%
Free cash flow
US$ -293,2M+54,2%
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap US$ 15,5BGeen K/W (bedrijfsverlies)
US$ 79,53+20,1%1Y
Since added +25,6%
B
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Gemengd
Getting better
Verslechtert
Revenue
US$ 945,5M+167,3%
Profit
US$ -573,8M+28,6%
Free cash flow
US$ -369,8M+36,9%
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap US$ 8,2BP/E 58,68
US$ 74,52-4,9%1Y
Since added -36,7%
A+
Groei en kasstroom
Groeit sterk
Business trend
Versnellend
Business quality
Sterk
Getting better
Gemengd
Revenue
US$ 963,6M+30,0%
Profit
US$ 162,3M+52,9%
Free cash flow
US$ 194,6M+19,2%
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap US$ 9,2BP/E 41,90
US$ 308,82+52,1%1Y
Since added -3,9%
A+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 470M+26,0%
Profit
US$ 225,2M+13,2%
Free cash flow
US$ 310,1M+87,3%
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.